Simon Agwale, PhD is the CEO of Innovative Biotech, Nigeria and Innovative Biotech USA Inc.  He has a vision for the development and investigation of HIV vaccine constructs from a prevalent Nigerian strain.

He is also currently developing novel vaccines against Covid-19, Ebola, HPV, and HIV using innovative viral-like particles (VLPs). Through Innovative Biotech, Dr Agwale is striving to further develop and refine these dynamic, novel treatments, expanding domestic end-to-end vaccine manufacturing capabilities in Nigeria to serve Africa.

Dr Agwale was a Postdoc fellow at the Institute of Human Virology Baltimore, USA and a visiting Scientist at various institutions in Brazil, Germany, UK including the US Vaccine Research Centre/NIH, and US CDC in Atlanta. He was West Africa’s representative on HIV/AIDS for Developing countries Coordinating Committee (DCCC) at the European and Developing Countries Clinical Trials Programme, where he was also the chair of the African Scientists committee.

Dr Agwale is the Vice Chair of AVMI’s Board of Directors and the lead of the Vaccine Technology working group. He was the lead and member of the Africa CDC-PAVM’s Technology Transfer and IP bold program and Talent Development workstreams respectively. Dr Simon Agwale was a Postdoc fellow at the Institute of Human Virology Baltimore, USA and Visiting Scientist at various institutions in Brazil, Germany, UK including the US Vaccine Research Centre/NIH, and US Centre for Disease Control and prevention in Atlanta. Dr Agwale was West Africa’s representative on HIV/AIDS for Developing countries Coordinating Committee (DCCC) at The European and Developing Countries Clinical Trials Programme (EDCTP), where he was also the chair of the African Scientists committee. He is a recipient of several scholarships, fellowships, and grants from reputable organizations around the world. He has also authored and co-authored numerous noteworthy publications.

Dr Agwale, Ph.D. is the CEO of Innovative Biotech, Nigeria, and Innovative Biotech USA Inc. He is a member of the board of the African Vaccine Manufacturing Initiative (AVMI) and Chair of Vaccine Technical working group. He is also an advisor to West Africa Health Organization (WAHO), and part of a recently established ECOWAS vaccines taskforce. He is currently the Lead of Bold Program 4 (Technology and IP) of the Partnerships for African Vaccine Manufacturing (PAVM) of Africa Centre for Disease Control and Prevention (Africa CDC).

Dr Agwale has a vision for the development and investigation of HIV vaccine constructs from prevalent Nigerian strains which are relevant to Nigerians. He is also currently developing novel vaccines against Covid-19, Ebola, HPV, and HIV using innovative viral-like particles (VLPs). Through INNOVATIVE, Dr Agwale is striving to further develop and refine these dynamic, novel treatments, and in doing so, expand domestic vaccine manufacturing capabilities in Nigeria to serve the African community.